Clinical Trial Search

Primary: Immunogenicity Screening Incidence to Detect the Presence of Anti-PegG-CSF Antibodies. — 10; 9; 0; 0 Participants

Primary: Safety Events — 6; 6; 6; 6 participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 0; 6; 14; 8 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of Emicizumab — 7.11 microgram per milliliter (μg/mL)

Primary: Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of LY3185643 and rGlucagon — 191; 658; 1110; 2010 picogram per milliliter (pg/mL)

Primary: Percentage of Brain Alpha5-Containing GABA-A Receptors Occupied by RO7017773

Primary: Part 1 Cohort A: Number of Participants With Non-serious Adverse Events (NSAEs) and Serious Adverse Events (SAEs) in CCI15106 — 0; 0; 0; 0 Participants

Primary: Number of Participants With Serious Adverse Events (SAEs) and Common (>=5%) Non-serious Adverse Events- Part 1 — 1; 1; 4; 4 Participants

Primary: Number of Subjects Experiencing TEAEs. — 3; 0; 4; 1 participants

Primary: Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free) — 2.629; 2.440; 1.893; 0.1381 nanogram per milliliter (ng/mL) — p=0.579

Primary: Post Operative Pain — 3.18; 2.27; 2.20; 1.39 score on a scale — p=0.083

Primary: AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC — 402.8; 452.3 microgram*day per…

Primary: Number of Subjects With Tumor Uptake of 111^In-CS-1008 in Target Lesions Based on Gamma Camera Imaging Following the Day 1 and Day 36 Infusions — 0; 3; 3; 3 participants

Primary: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia — 66; 66 Participants

Primary: Maximum Tolerated Dose (MTD) of Olaparib — 50 mg twice daily